Unknown

Dataset Information

In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring.


ABSTRACT:

Background

17α-hydroxyprogesterone caproate is a synthetic progestogen initially approved in the 1950s to treat gynecologic and obstetrical conditions. Despite continued concerns about safety and short-term efficacy regarding the use of 17α-hydroxyprogesterone caproate for the prevention of preterm birth in pregnant women, little is known about the long-term effects of 17α-hydroxyprogesterone caproate on the health of the offsprings.

Objective

To examine the association between in utero exposure to 17α-hydroxyprogesterone caproate and the risk of cancer in the offspring.

Study design

The Child Health and Development Studies was a population-based cohort of >18,000 mother-child dyads receiving prenatal care in the Kaiser Foundation Health Plan (Oakland, CA) between 195

SUBMITTER: Murphy CC 

PROVIDER: S-EPMC8748293 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature